Keywords: Depomed, Gralise, Abbott Labs, Boehringer Ingelheim, Acuform, Glumetza, Herpectic neuralgia, Type 2 diabetes

Depomed regains rights to Gralise from Abbott; licenses Acuform to Boehringer Ingelheim

Article | 18 March 2011

Print This

Following a period of mediation, USA-based Depomed (Nasdaq: DEPO) will regain rights to its shingles drug Gralise (gabapentin) from drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in